Profile data is unavailable for this security.
About the company
FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
- Revenue in INR (TTM)19.43bn
- Net income in INR3.05bn
- Incorporated1940
- Employees6.37k
- LocationF D C Ltd142-148, S.V. Road, Jogeshwari (W)MUMBAI 400053IndiaIND
- Phone+91 2 226739100
- Fax+91 2 226300614
- Websitehttps://www.fdcindia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Advanced Enzyme Technologies Ltd | 6.24bn | 1.33bn | 40.57bn | 338.00 | 30.41 | 3.06 | 23.56 | 6.50 | 11.93 | 11.93 | 55.83 | 118.41 | 0.4219 | 1.06 | 6.27 | -- | 9.26 | 10.82 | 10.23 | 11.93 | 76.83 | 72.81 | 21.95 | 24.59 | 6.22 | 57.81 | 0.0334 | 15.17 | 15.39 | 8.26 | 26.19 | 3.72 | 27.85 | 53.42 |
Aarti Drugs Ltd | 25.29bn | 1.71bn | 43.84bn | 1.50k | 25.63 | 3.42 | 19.66 | 1.73 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
Shilpa Medicare Ltd | 11.51bn | 318.74m | 47.49bn | 1.03k | 131.96 | 2.33 | 33.96 | 4.12 | 3.68 | 3.68 | 134.51 | 208.37 | 0.3841 | 1.23 | 3.21 | -- | 1.07 | 2.84 | 1.41 | 3.65 | 64.63 | 61.37 | 2.78 | 7.03 | 0.7671 | 1.41 | 0.3424 | -- | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
Orchid Pharma Ltd | 8.19bn | 915.95m | 50.86bn | 838.00 | 52.39 | 4.35 | 39.82 | 6.21 | 19.14 | 19.14 | 169.90 | 230.58 | 0.5897 | 1.97 | 3.99 | -- | 6.80 | -0.9734 | 8.80 | -1.40 | 40.87 | 43.32 | 11.53 | -2.40 | 2.03 | 4.68 | 0.1031 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 50.93bn | 1.40k | 23.48 | 2.90 | 17.56 | 2.75 | 23.94 | 23.94 | 204.45 | 193.89 | 0.7698 | 1.64 | 3.86 | -- | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.01 | 18.17 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 66.32bn | -- | 40.48 | 7.85 | 34.57 | 9.32 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 66.80bn | 407.00 | -- | 53.12 | -- | 88.42 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
Marksans Pharma Ltd | 21.03bn | 3.17bn | 67.32bn | 1.40k | 21.08 | -- | 17.39 | 3.20 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
F D C Ltd | 19.43bn | 3.05bn | 70.42bn | 6.37k | 23.24 | 3.36 | 20.41 | 3.62 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 77.52bn | 1.57k | 25.83 | 6.04 | 21.55 | 4.97 | 233.89 | 233.89 | 1,214.80 | 999.78 | 0.9135 | 2.33 | 4.24 | -- | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.21 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 78.03bn | 1.41k | 36.48 | -- | 32.41 | 6.68 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
Strides Pharma Science Ltd | 40.51bn | -1.25bn | 79.12bn | 2.85k | -- | 3.72 | 109.66 | 1.95 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
Wockhardt Ltd | 27.98bn | -4.63bn | 81.20bn | 2.74k | -- | 2.43 | -- | 2.90 | -32.04 | -32.04 | 193.86 | 218.12 | 0.365 | 1.80 | 3.95 | -- | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.79 | -16.87 | -12.70 | 0.5532 | -0.1906 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 97.99bn | 777.00 | 21.54 | 4.23 | 19.03 | 5.78 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
Granules India Ltd | 45.06bn | 4.05bn | 101.43bn | 3.65k | 25.01 | 3.14 | 16.56 | 2.25 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 102.46bn | 1.82k | 21.79 | 4.39 | 19.54 | 4.49 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
Holder | Shares | % Held |
---|---|---|
ICICI Prudential Asset Management Co. Ltd.as of 13 Jun 2023 | 8.44m | 5.18% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Apr 2024 | 4.30m | 2.64% |
Dimensional Fund Advisors LPas of 09 May 2024 | 875.41k | 0.54% |
Bandhan Asset Management Co. Ltd.as of 30 Apr 2024 | 492.17k | 0.30% |
Tata Asset Management Ltd.as of 30 Apr 2024 | 471.28k | 0.29% |
Samco Asset Management Pvt. Ltd.as of 30 Apr 2024 | 429.10k | 0.26% |
SSgA Funds Management, Inc.as of 09 May 2024 | 329.12k | 0.20% |
BlackRock Fund Advisorsas of 09 May 2024 | 310.39k | 0.19% |
BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 150.57k | 0.09% |
ITI Asset Management Ltd. (India)as of 30 Apr 2024 | 69.87k | 0.04% |